Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study (vol 26, pg 3523, 2008)

被引：1
|
作者：
Hochster
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 28期
关键词：
D O I：
10.1200/JCO.2008.19.8630
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4697 / 4697
页数：1
相关论文
共 50 条
  • [31] Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer
    Cunningham, D.
    Sirohi, B.
    Pluzanska, A.
    Utracka-Hutka, B.
    Zaluski, J.
    Glynne-Jones, R.
    Koralewski, P.
    Bridgewater, J.
    Mainwaring, P.
    Wasan, H.
    Wang, J.-Y.
    Szczylik, C.
    Clingan, P.
    Chan, R. T. T.
    Tabah-Fisch, I.
    Cassidy, J.
    ANNALS OF ONCOLOGY, 2009, 20 (02) : 244 - 250
  • [32] Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
    Van Cutsem, E.
    Rivera, F.
    Berry, S.
    Kretzschmar, A.
    Michael, M.
    DiBartolomeo, M.
    Mazier, M. -A.
    Canon, J. -L.
    Georgoulias, V.
    Peeters, M.
    Bridgewater, J.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2009, 20 (11) : 1842 - 1847
  • [33] Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study
    Kotani, Daisuke
    Yoshino, Takayuki
    Kotaka, Masahito
    Kawazoe, Akihito
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Yamazaki, Kentaro
    Yamanaka, Takeharu
    Oki, Eiji
    Muro, Kei
    Komatsu, Yoshito
    Bando, Hideaki
    Satake, Hironaga
    Kato, Takeshi
    Tsuji, Akihito
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1649 - 1655
  • [34] The efficacy and safety of first-line and salvage therapies with bevacizumab combination chemotherapy regimens in metastatic colorectal cancer: A retrospective ASMO experience.
    Yildiz, Ramazan
    Buyukberber, Suleyman
    Koca, Dogan
    Korai, Lokman
    Ciltas, Aydin
    Unal, Olcun Umit
    Gumus, Mahmut
    Ozdemir, Nuriye
    Dane, Faysal
    Berk, Veil
    Kaplan, Mehmet Ali
    Elkiran, Tamer
    Boruban, Melih Cern
    Coskun, Ugur
    Aydin, Dincer
    Uncu, Dogan
    Ozkan, Metin
    Isikdogan, Abdurrahman
    Benekli, Mustafa
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Beltran, C.
    VALUE IN HEALTH, 2011, 14 (07) : A435 - A435
  • [36] SAFETY AND EFFICACY OF BEVACIZUMAB PLUS STANDARD FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER: FIRST BEAT
    Van Cutsem, E.
    Berry, S.
    Michael, M.
    Kretzschmar, A.
    Rivera, F.
    DiBartolomeo, M.
    Mazier, M.
    Andre, N.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 125 - 125
  • [37] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study
    Antonuzzo, Lorenzo
    Giommoni, Elisa
    Pastorelli, Davide
    Latiano, Tiziana
    Pavese, Ida
    Azzarello, Domenico
    Aieta, Michele
    Pastina, Ilaria
    Di Fabio, Francesca
    Bertolini, Alessandro
    Corsi, Domenico Cristiano
    Mogavero, Selene
    Angelini, Valentina
    Pazzagli, Mario
    Di Costanzo, Francesco
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (23) : 7281 - 7288
  • [38] Safety and efficacy of first-line XELIRI with or without bevacizumab in patients with metastatic colorectal cancer: Analysis of two phase II studies
    Garcia-Alfonso, P.
    Alvarez, S.
    Munoz, A.
    Lopez, P.
    Riesco, C.
    Adeva, J.
    Martin, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [39] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer:The OBELIX study
    Lorenzo Antonuzzo
    Elisa Giommoni
    Davide Pastorelli
    Tiziana Latiano
    Ida Pavese
    Domenico Azzarello
    Michele Aieta
    Ilaria Pastina
    Francesca Di Fabio
    Alessandro Bertolini
    Domenico Cristiano Corsi
    Selene Mogavero
    Valentina Angelini
    Mario Pazzagli
    Francesco Di Costanzo
    World Journal of Gastroenterology, 2015, (23) : 7281 - 7288
  • [40] Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients
    Thierry Landre
    Emilie Maillard
    Chérifa Taleb
    Djamel Ghebriou
    Gaetan Des Guetz
    Laurent Zelek
    Thomas Aparicio
    International Journal of Colorectal Disease, 2018, 33 : 1125 - 1130
12345